BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26819056)

  • 1. Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia.
    Rasi S; Khiabanian H; Ciardullo C; Terzi-di-Bergamo L; Monti S; Spina V; Bruscaggin A; Cerri M; Deambrogi C; Martuscelli L; Biasi A; Spaccarotella E; De Paoli L; Gattei V; Foà R; Rabadan R; Gaidano G; Rossi D
    Haematologica; 2016 Apr; 101(4):e135-8. PubMed ID: 26819056
    [No Abstract]   [Full Text] [Related]  

  • 2. NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
    Chiaretti S; Marinelli M; Del Giudice I; Bonina S; Piciocchi A; Messina M; Vignetti M; Rossi D; Di Maio V; Mauro FR; Guarini A; Gaidano G; Foà R
    Leuk Lymphoma; 2014 Dec; 55(12):2785-92. PubMed ID: 24597984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
    Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
    Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
    Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
    Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2.
    Strefford JC; Sutton LA; Baliakas P; Agathangelidis A; Malčíková J; Plevova K; Scarfó L; Davis Z; Stalika E; Cortese D; Cahill N; Pedersen LB; di Celle PF; Tzenou T; Geisler C; Panagiotidis P; Langerak AW; Chiorazzi N; Pospisilova S; Oscier D; Davi F; Belessi C; Mansouri L; Ghia P; Stamatopoulos K; Rosenquist R
    Leukemia; 2013 Nov; 27(11):2196-9. PubMed ID: 23558524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.
    Sutton LA; Ljungström V; Mansouri L; Young E; Cortese D; Navrkalova V; Malcikova J; Muggen AF; Trbusek M; Panagiotidis P; Davi F; Belessi C; Langerak AW; Ghia P; Pospisilova S; Stamatopoulos K; Rosenquist R
    Haematologica; 2015 Mar; 100(3):370-6. PubMed ID: 25480502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel prognostic gene mutations identified in chronic lymphocytic leukemia and their impact on clinical practice.
    Campregher PV; Hamerschlak N
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):271-6. PubMed ID: 24548608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT.
    Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV; Saenko V; Bazyka DA
    Probl Radiac Med Radiobiol; 2018 Dec; 23():283-301. PubMed ID: 30582853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort.
    Cortese D; Sutton LA; Cahill N; Smedby KE; Geisler C; Gunnarsson R; Juliusson G; Mansouri L; Rosenquist R
    Leukemia; 2014 Mar; 28(3):710-3. PubMed ID: 24217197
    [No Abstract]   [Full Text] [Related]  

  • 10. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.
    Rossi D; Rasi S; Spina V; Bruscaggin A; Monti S; Ciardullo C; Deambrogi C; Khiabanian H; Serra R; Bertoni F; Forconi F; Laurenti L; Marasca R; Dal-Bo M; Rossi FM; Bulian P; Nomdedeu J; Del Poeta G; Gattei V; Pasqualucci L; Rabadan R; Foà R; Dalla-Favera R; Gaidano G
    Blood; 2013 Feb; 121(8):1403-12. PubMed ID: 23243274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chronic lymphocytic leukemia: diagnosis and gene mutations].
    Aoki S
    Rinsho Ketsueki; 2014 Oct; 55(10):1981-8. PubMed ID: 25297763
    [No Abstract]   [Full Text] [Related]  

  • 12. New boys in town: prognostic role of SF3B1, NOTCH1 and other cryptic alterations in chronic lymphocytic leukemia and how it works.
    Filip AA
    Leuk Lymphoma; 2013 Sep; 54(9):1876-81. PubMed ID: 23343182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.
    Dal Bo M; Bulian P; Bomben R; Zucchetto A; Rossi FM; Pozzo F; Tissino E; Benedetti D; Bittolo T; Nanni P; Cattarossi I; Zaina E; Chivilò H; Degan M; Zaja F; Pozzato G; Chiarenza A; Di Raimondo F; Del Principe MI; Del Poeta G; Rossi D; Gaidano G; Gattei V
    Leukemia; 2016 Oct; 30(10):2011-2018. PubMed ID: 27109509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of NOTCH1, MYD88, and SF3B1 mutations in Polish patients with chronic lymphocytic leukemia.
    Putowski M; Podgórniak M; Piróg M; Knap J; Zaleska J; Purkot J; Zawiślak J; Zakrzewska E; Karczmarczyk A; Własiuk P; Subocz E; Giannopoulos K
    Pol Arch Intern Med; 2017 Apr; 127(4):238-244. PubMed ID: 28424451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A reduced panel of eight genes (ATM, SF3B1, NOTCH1, BIRC3, XPO1, MYD88, TNFAIP3, and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia.
    Chauzeix J; Pastoret C; Donaty L; Gachard N; Fest T; Feuillard J; Rizzo D
    Int J Lab Hematol; 2021 Aug; 43(4):683-692. PubMed ID: 33325634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.
    Schnaiter A; Paschka P; Rossi M; Zenz T; Bühler A; Winkler D; Cazzola M; Döhner K; Edelmann J; Mertens D; Kless S; Mack S; Busch R; Hallek M; Döhner H; Stilgenbauer S
    Blood; 2013 Aug; 122(7):1266-70. PubMed ID: 23821658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome.
    Rossi D; Rasi S; Spina V; Fangazio M; Monti S; Greco M; Ciardullo C; Famà R; Cresta S; Bruscaggin A; Laurenti L; Martini M; Musto P; Forconi F; Marasca R; Larocca LM; Foà R; Gaidano G
    Br J Haematol; 2012 Aug; 158(3):426-9. PubMed ID: 22571487
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation.
    Onaindia A; Gómez S; Piris-Villaespesa M; Martínez-Laperche C; Cereceda L; Montes-Moreno S; Batlle A; de Villambrosia SG; Pollán M; Martín-Acosta P; González-Rincón J; Menarguez J; Alvés J; Rodriguez-Pinilla SM; García JF; Mollejo M; Fraga M; García-Marco JA; Piris MA; Sánchez-Beato M
    Haematologica; 2015 May; 100(5):e200-3. PubMed ID: 25552700
    [No Abstract]   [Full Text] [Related]  

  • 19. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.
    Stilgenbauer S; Schnaiter A; Paschka P; Zenz T; Rossi M; Döhner K; Bühler A; Böttcher S; Ritgen M; Kneba M; Winkler D; Tausch E; Hoth P; Edelmann J; Mertens D; Bullinger L; Bergmann M; Kless S; Mack S; Jäger U; Patten N; Wu L; Wenger MK; Fingerle-Rowson G; Lichter P; Cazzola M; Wendtner CM; Fink AM; Fischer K; Busch R; Hallek M; Döhner H
    Blood; 2014 May; 123(21):3247-54. PubMed ID: 24652989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic correlation of NOTCH1 and SF3B1 mutations with chromosomal abnormalities in chronic lymphocytic leukemia patients.
    Sadria R; Motamed N; Saberi Anvar M; Mehrabani Yeganeh H; Poopak B
    Cancer Rep (Hoboken); 2023 Mar; 6(3):e1757. PubMed ID: 36411516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.